Agios Pharmaceuticals, Inc.(AGIO)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$29.52
- 52-Week Range
- $22.24 – $46.00
- YTD
- +8.61%
- IV Rank (30D)
- 17.71
- Straddle Price
- $4.70
- P/C Vol Ratio
- 0.14
- Market Cap
- $1.7B
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.53% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 10.03% (VRP-adj) |
| WACC | 10.01% |
| Volatility Risk Premium | +36.2pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.4B |
| Return on Equity (TTM) | -38.1% |
| Book / Price | 66.3% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 90.0% |
| FCF Margin (TTM) | -582.5% |
| Debt / Equity | 0.00 |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $29.28 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $28.37 |
| Bollinger Width / SMA20 | 38.1% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $2B |
Peers used for multiples: EW, NBIX, REGN, UTHR
(filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$45.15
Current Price
$29.46
Deviation
+50.0%
Forward-Return Rank
LONG
gates ✓
?
| Horizon | Expected α | z Pred | Blended z | Rank % | Active? |
|---|---|---|---|---|---|
| 21d | +0.5% | +1.05 | +1.46 | 88.6% | — |
| 42d | +2.6% | +1.67 | +1.77 | 91.7% | — |
| 63d | +2.4% | +1.31 | +1.59 | 88.6% | — |
Expected α = forward-return point estimate vs SPY (e.g., +7.5% means the predictor expects this stock to outperform SPY by 7.5% over that horizon).
For SHORT direction the model uses a different ranking metric (conviction-weighted deviation, not the LGBM prediction); Expected α is shown for reference.
⚠ flags rows where Expected α disagrees with the FV direction — two independent signals are in conflict; conviction is low even if rank looks extreme.
Forward-Return Rank. A proprietary ensemble of a machine-learning forward-return model and a conviction-weighted fundamental score, ranked cross-sectionally each day across the S&P 500 (and broader universes on the screener). Each stock is scored at three horizons (21/42/63 trading days). "Active" = top/bottom 5% AND all risk filters pass. Backtested mean alpha vs SPY on active picks: 21d LONG +13.4%, 63d +34.9% (S&P 500, walk-forward). Past performance is not indicative of future results.
Value vs momentum conflict ⚠. The "FV direction" (long/short) comes from the fundamentals-based engine — price vs intrinsic value. The "Expected α" comes from a separate machine-learning predictor trained on ~12 features (sector, options-implied move, beta, institutional flow, etc.). Sometimes the two disagree: a stock is overvalued by fundamentals but the predictor expects it to keep outperforming (sector or momentum tailwinds). When all 3 horizons disagree, treat the direction signal as low-conviction — neither model is strongly recommending a position.
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 21.1× · 4 peers |
| Peer EV/EBITDA | n/a | 0% | median 17.1× · 4 peers |
| Peer P/B | $82.51 | 50% | median 4.3× · 4 peers |
| Peer P/S | $7.80 | 50% | median 6.2× · 4 peers |
| Market Anchor (SMA50) | $29.28 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-06-12 · updated 2026-06-12 20:59:55.687000
Info
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $1.7B
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and …
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +2.05% | 6 |
| Feb | +6.40% | 6 |
| Mar | -3.77% | 6 |
| Apr | -2.79% | 6 |
| May | +5.93% | 6 |
| Jun | +4.67% | 6 |
| Jul | +2.16% | 5 |
| Aug | +0.86% | 5 |
| Sep | -2.42% | 5 |
| Oct | +0.42% | 5 |
| Nov | -1.68% | 5 |
| Dec | -12.23% | 5 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $28.41
SMA 50: $29.19
SMA 200: $31.85
Current: $29.46
EMA 12: $28.51
EMA 26: $28.48
MACD: 0.0342 | Signal: 0.1329
BEARISH
ADX (14): 9.93
RANGE
+DI: 26.09
−DI: 18.12
Momentum Oscillators
RSI (14): 55.04
NEUTRAL
Stoch %K: 63.08
Stoch %D: 52.43
Williams %R: -26.16
Volume & Volatility
BB Upper: $30.01
BB Lower: $26.81
NEUTRAL
OBV: -936,810
Vol SMA 20: 917,353
Vol ROC: -20.45%
ATR: $1.38
True Range: $1.72
HV 20: 50.3%
HV 30: 42.4%
HV 60: 75.5%
Data Summary
Data Points: 500
Last Updated: 2026-06-12T21:15:12.293000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Earnings History
8 of 8 under expected move
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-01 | Pre-Market | 10.11% | 3.26% | 0.32x | Within |
| 2024-10-31 | Pre-Market | 10.26% | 5.90% | 0.58x | Within |
| 2025-02-13 | Pre-Market | 14.17% | 1.49% | 0.11x | Within |
| 2025-05-01 | Pre-Market | 7.43% | 3.64% | 0.49x | Within |
| 2025-07-31 | After-Close | 11.22% | 5.96% | 0.53x | Within |
| 2025-10-30 | Pre-Market | 13.82% | 2.91% | 0.21x | Within |
| 2026-02-12 | Pre-Market | 15.68% | 1.56% | 0.10x | Within |
| 2026-04-29 | After-Close | 12.57% | 0.18% | 0.01x | Within |
Options Activity
- IV Rank (30D)
- 17.71
- IV Rank (7D)
- 100
- Avg IV
- 75.4%
- Straddle (30D)
- $4.70
- Straddle (7D)
- $2.48
- P/C Volume
- 0.14
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 0.94
- Correlation (SPY)
- 15.5%
- R²
- 0.02
- Ann. Volatility
- 74.9%
- SPY Volatility
- 12.3%
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
? 13F Guide
Diluted shares outstanding: 58,206,524 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
14 filers$127.30M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | ARMISTICE CAPITAL, LLC | $108.26M | 85.04% | 2026-03-31 |
| 2 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $3.95M | 3.11% | 2026-03-31 |
| 3 | Caligan Partners LP | $3.04M | 2.39% | 2026-03-31 |
| 4 | GROUP ONE TRADING LLC Custodian | $2.25M | 1.77% | 2026-03-31 |
| 5 | CITADEL ADVISORS LLC Custodian | $2.22M | 1.75% | 2026-03-31 |
| 6 | CITIGROUP INC Custodian | $2.13M | 1.67% | 2026-03-31 |
| 7 | JANE STREET GROUP, LLC Custodian | $1.66M | 1.30% | 2026-03-31 |
| 8 | JPMORGAN CHASE & CO Custodian | $888.30K | 0.70% | 2026-03-31 |
| 9 | BOOTHBAY FUND MANAGEMENT, LLC | $866.05K | 0.68% | 2026-03-31 |
| 10 | Point72 Asset Management, L.P. | $497.30K | 0.39% | 2026-03-31 |
| 11 | TUDOR INVESTMENT CORP ET AL | $463.47K | 0.36% | 2026-03-31 |
| 12 | WOLVERINE TRADING, LLC Custodian | $447.68K | 0.35% | 2025-09-30 |
| 13 | GOLDMAN SACHS GROUP INC Custodian | $402.58K | 0.32% | 2026-03-31 |
| 14 | SIMPLEX TRADING, LLC Custodian | $216.51K | 0.17% | 2026-03-31 |
9 filers$17.63M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | JANE STREET GROUP, LLC Custodian | $3.62M | 20.56% | 2026-03-31 |
| 2 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $3.20M | 18.14% | 2026-03-31 |
| 3 | GROUP ONE TRADING LLC Custodian | $3.07M | 17.41% | 2026-03-31 |
| 4 | CITADEL ADVISORS LLC Custodian | $2.85M | 16.14% | 2026-03-31 |
| 5 | CITIGROUP INC Custodian | $2.13M | 12.07% | 2026-03-31 |
| 6 | NOMURA HOLDINGS INC | $1.01M | 5.76% | 2026-03-31 |
| 7 | JPMORGAN CHASE & CO Custodian | $897.18K | 5.09% | 2026-03-31 |
| 8 | Point72 Asset Management, L.P. | $497.30K | 2.82% | 2026-03-31 |
| 9 | SIMPLEX TRADING, LLC Custodian | $355.21K | 2.02% | 2026-03-31 |
Insider Activity
Latest: 2026-04-06
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-04-06 | Tsveta Milanova | Chief Commercial Officer | Mixed | +5,238 | $34.71 | -$113.2K | EDGAR |
| 2026-04-06 | James William Burns | Chief Legal Officer | Mixed | +5,220 | $34.71 | -$113.8K | EDGAR |
| 2026-04-06 | Cecilia Jones | Chief Financial Officer | Mixed | +5,359 | $34.71 | -$109.0K | EDGAR |
| 2026-04-06 | Krishnan Viswanadhan | Chief Corp Dev & Strategy | Mixed | +5,141 | $34.71 | -$102.7K | EDGAR |
| 2026-04-06 | Brian Goff | Chief Executive Officer | Mixed | +19,960 | $34.71 | -$661.9K | EDGAR |
| 2026-04-06 | Sarah Gheuens | Chief Medical Officer | Mixed | +5,560 | $34.71 | -$102.0K | EDGAR |
| 2026-03-09 | Krishnan Viswanadhan | Chief Corp Dev & Strategy | Mixed | +5,141 | $27.80 | -$82.3K | EDGAR |
| 2026-03-05 | Theodore James Jr. Washburn | Principal Accounting Officer | Sell (S) | −5,272 | $28.88 | -$152.3K | EDGAR |
| 2026-03-03 | Krishnan Viswanadhan | Chief Corp Dev & Strategy | Grant (A) | +66,000 opt | — | EDGAR | |
| 2026-03-03 | Theodore James Jr. Washburn | Principal Accounting Officer | Mixed | +5,272 | $28.96 | -$64.4K | EDGAR |
| 2026-03-03 | Cecilia Jones | Chief Financial Officer | Mixed | +11,934 | $28.96 | -$145.8K | EDGAR |
| 2026-03-03 | James William Burns | Chief Legal Officer | Mixed | +12,368 | $28.96 | -$151.1K | EDGAR |
| 2026-03-03 | Sarah Gheuens | Chief Medical Officer | Mixed | +9,611 | $28.96 | -$117.4K | EDGAR |
| 2026-03-03 | Brian Goff | Chief Executive Officer | Mixed | +21,445 | $28.96 | -$522.9K | EDGAR |
| 2026-03-03 | Tsveta Milanova | Chief Commercial Officer | Mixed | +6,798 | $28.96 | -$83.1K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
39 insiders · @ $29.46
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | CELGENE CORP /DE/ | 10%+ Owner | 6,718,433 | $197.93M | $618.13M | 4 | 2018-01-31 |
| 2 | Celgene European Investment Co LLC | 10%+ Owner | 5,788,750 | $170.54M | $75.32M | 2 | 2019-11-14 |
| 3 | Flagship Ventures Fund 2007, L.P. | 10%+ Owner | 3,860,738 | $113.74M | $0 | 1 | 2013-07-31 |
| 4 | CLINTON BYBEE | 10%+ Owner | 3,088,590 | $90.99M | $0 | 2 | 2015-02-23 |
| 5 | THIRD ROCK VENTURES LP | 10%+ Owner | 3,070,090 | $90.44M | $0 | 1 | 2014-09-12 |
| 6 | KEVIN P STARR | Director | 944,581 | $27.83M | $0 | 3 | 2015-02-19 |
| 7 | David P Schenkein | Director | 397,014 | $11.70M | -$62.02M | 86 | 2024-06-24 |
| 8 | Brian Goff | Chief Executive Officer | 177,604 | $5.23M | -$5.41M | 15 | 2026-04-06 |
| 9 | JACQUALYN A FOUSE | Director | 151,340 | $4.46M | $112.3K | 23 | 2025-06-23 |
| 10 | John Duncan Higgons | Chief Operating Officer | 120,834 | $3.56M | -$21.43M | 34 | 2016-01-05 |
| 11 | ROBERT NELSEN | Director | 118,404 | $3.49M | -$20.75M | 10 | 2017-03-07 |
| 12 | Lewis Clayton Jr. Cantley | Director | 101,654 | $2.99M | -$12.81M | 33 | 2017-12-08 |
| 13 | Scott Biller | Chief Scientific Officer | 86,788 | $2.56M | -$23.78M | 78 | 2019-06-13 |
| 14 | Sarah Gheuens | Chief Medical Officer | 80,277 | $2.36M | -$1.78M | 25 | 2026-04-06 |
| 15 | Cecilia Jones | Chief Financial Officer | 54,998 | $1.62M | -$895.7K | 13 | 2026-04-06 |
| 16 | James William Burns | Chief Legal Officer | 52,586 | $1.55M | -$2.10M | 20 | 2026-04-06 |
| 17 | Tsveta Milanova | Chief Commercial Officer | 50,091 | $1.48M | -$741.9K | 12 | 2026-04-06 |
| 18 | JOHN MARAGANORE | Director | 30,028 | $884.6K | -$1.80M | 18 | 2022-06-23 |
| 19 | Andrew Hirsch | Chief Financial Officer | 24,272 | $715.1K | $0 | 12 | 2020-04-24 |
| 20 | Jonathan Biller | Chief Financial Officer | 22,953 | $676.2K | $0 | 8 | 2022-03-03 |
| 21 | Bruce Car | Chief Scientific Officer | 18,793 | $553.6K | $0 | 8 | 2022-03-03 |
| 22 | David Scadden | Director | 17,603 | $518.6K | -$81.5K | 21 | 2025-11-14 |
| 23 | Maykin Ho | Director | 17,032 | $501.8K | $0 | 15 | 2025-06-23 |
| 24 | Christopher Bowden | Chief Medical Officer | 15,487 | $456.2K | -$13.23M | 35 | 2021-06-22 |
| 25 | Rahul D. Ballal | Director | 12,414 | $365.7K | -$1.12M | 9 | 2025-08-13 |
| 26 | Cynthia Smith | Director | 12,414 | $365.7K | $0 | 8 | 2025-08-13 |
| 27 | Steven L. Hoerter | Chief Commercial Officer | 10,941 | $322.3K | -$3.75M | 16 | 2019-03-05 |
| 28 | Krishnan Viswanadhan | Chief Corp Dev & Strategy | 10,282 | $302.9K | -$185.0K | 4 | 2026-04-06 |
| 29 | Glenn Goddard | Senior Vice President, Finance | 10,000 | $294.6K | -$9.53M | 21 | 2016-02-18 |
| 30 | Kaye I Foster-Cheek | Director | 9,668 | $284.8K | -$2.24M | 23 | 2025-06-23 |
| 31 | Richa Poddar | Chief Commercial Officer | 8,508 | $250.6K | $0 | 5 | 2022-10-18 |
| 32 | Darrin Miles | Chief Commercial Officer | 7,209 | $212.4K | -$321.7K | 5 | 2021-05-18 |
| 33 | Paul J Clancy | Director | 6,549 | $192.9K | $0 | 12 | 2022-06-23 |
| 34 | IAN T CLARK | Director | 6,549 | $192.9K | $0 | 8 | 2022-05-24 |
| 35 | Adams Catherine Owen | Director | 6,073 | $178.9K | $0 | 5 | 2025-06-23 |
| 36 | JEFFREY D CAPELLO | Director | 6,073 | $178.9K | $0 | 5 | 2025-06-23 |
| 37 | Douglas G. Cole | Director | 2,778 | $81.8K | $0 | 3 | 2016-08-11 |
| 38 | Carman Alenson | Principal Accounting Officer | 1,777 | $52.4K | -$773.2K | 23 | 2021-06-23 |
| 39 | Theodore James Jr. Washburn | Principal Accounting Officer | 868 | $25.6K | -$1.06M | 24 | 2026-03-05 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 1.5 |
| P/S Ratio | 25.9 |
| EV/EBITDA | -3.4 |
| TTM Revenue | $0.1B |
| TTM Net Income | $-0.4B |
| TTM EPS | $-7.25 |
| ROE | -38.1% |